Correction: Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket (Journal of Medicinal Chemistry (2016) 59 (10163-10175) DOI: 10.1021/acs.jmedchem.6b00927);Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl- l -methionine Pocket

Journal of Medicinal Chemistry

Volumn 59, Issue 22, 2016, Pages 10163-10175

  Lerner, Christian ^a   Jakob Roetne, Roland ^a   Buettelmann, Bernd ^a   Ehler, Andreas ^a   Rudolph, Markus ^a   Sarmiento, Rosa María Rodríguez ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; S ADENOSYLMETHIONINE;

ARTICLE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENZYMATIC ASSAY; IC50; LIGAND BINDING; PARKINSON DISEASE; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; MOLECULAR MODEL; PRECLINICAL STUDY; SYNTHESIS;

CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; S-ADENOSYLMETHIONINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84999663797     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00613     Document Type: Erratum

References (34)

1. Apud, J. A.; Weinberger, D. R. Treatment of Cognitive Deficits Associated with Schizophrenia, Potential Role of Catechol-O-Methyltransferase Inhibitors CNS Drugs 2007, 21, 535-557 10.2165/00023210-200721070-00002
2. O'Tuathaigh, C. M. P.; Desbonnet, L.; Lee, P.; Waddington, J. L. Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia CNS Neurol. Disord.: Drug Targets 2012, 11, 282-291 10.2174/187152712800672418
3. Kiss, L. E.; Soares-da-Silva, P. Medicinal Chemistry of Catechol O-Methyltransferase (COMT) Inhibitors and their Therapeutic Utility J. Med. Chem. 2014, 57, 8692-8717 10.1021/jm500572b
4. Jorga, K.; Fotteler, B.; Heizmann, P.; Gasser, R. Metabolism and Excretion of Tolcapone, a Novel Inhibitor of Catechol-O-Methyltransferase Br. J. Clin. Pharmacol. 1999, 48, 513-520 10.1046/j.1365-2125.1999.00036.x
5. Bonifácio, M. J.; Palma, P. N.; Almeida, L.; Soares-da-Silva, P. Catechol-O-Methyltransferase and its Inhibitors in Parkinson's Disease CNS Drug Rev. 2007, 13, 352-379 10.1111/j.1527-3458.2007.00020.x
6. Forsberg, M.; Lehtonen, M.; Heikkinen, M.; Savolainen, J.; Järvinen, T.; Männistö, P. T. Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat J. Pharmacol. Exp. Ther. 2003, 304, 498-506 10.1124/jpet.102.042846
7. 18F-Dopa PET Evidence that Tolcapone Acts as a Central COMT Inhibitor in Parkinson's Disease Synapse 2002, 43, 201-207 10.1002/syn.10034
8. Lerner, C.; Ruf, A.; Gramlich, V.; Masjost, B.; Zürcher, G.; Jakob-Roetne, R.; Borroni, E.; Diederich, F. X-ray Crystal Structure of a Bisubstrate Inhibitor Bound to the Enzyme Catechol-O-Methyltransferase: A Dramatic Effect of Inhibitor Preorganization on Binding Affinity Angew. Chem., Int. Ed. 2001, 40, 4040-4042 10.1002/1521-3773(20011105)40:21<4040::AID-ANIE4040>3.0.CO;2-C
9. Paulini, R.; Lerner, C.; Jakob-Roetne, R.; Zürcher, G.; Borroni, E.; Diederich, F. Bisubstrate Inhibitors of the Enzyme Catechol O-Methyltransferase (COMT): Efficient Inhibition Despite the Lack of a Nitro Group ChemBioChem 2004, 5, 1270-1274 10.1002/cbic.200400084
10. Ellermann, M.; Lerner, C.; Burgy, G.; Ehler, A.; Bissantz, C.; Jakob-Roetne, R.; Paulini, R.; Allemann, O.; Tissot, H.; Grunstein, D.; Stihle, M.; Diederich, F.; Rudolph, M. G. Catechol-O-Methyltransferase in Complex with Substituted 3′-Deoxyribose Bisubstrate Inhibitors Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012, 68, 253-260 10.1107/S0907444912001138
11. Ellermann, M.; Paulini, R.; Jakob-Roetne, R.; Lerner, C.; Borroni, E.; Roth, D.; Ehler, A.; Schweizer, W. B.; Schlatter, D.; Rudolph, M. G.; Diederich, F. Molecular Recognition at the Active Site of Catechol-O-methyltransferase (COMT): Adenine Replacements in Bisubstrate Inhibitors Chem.-Eur. J. 2011, 17, 6369-6381 10.1002/chem.201003648
12. In vivo properties of hydroxypyridones derivatives are discussed where compounds required very high doses to reach meaningful brain exposure: Robinson, R. G.; Smith, S. M.; Wolkenberg, S. E.; Kandebo, M.; Yao, L.; Gibson, C. R.; Harrison, S. T.; Polsky-Fisher, S.; Barrow, J. C.; Manley, P. J.; Mulhearn, J. J.; Nanda, K. K.; Schubert, J. W.; Trotter, B. W.; Zhao, Z.; Sanders, J. M.; Smith, R. F.; McLoughlin, D.; Sharma, S.; Hall, D. L.; Walker, T. L.; Kershner, J. L.; Bhandari, N.; Hutson, P. H.; Sachs, N. A. Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-Methyltransferase Inhibitors and Substrates ACS Chem. Neurosci. 2012, 3, 129-140 10.1021/cn200109w
13. Wu, B.; Kulkarni, K.; Basu, S.; Zhang, S.; Hu, M. First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics J. Pharm. Sci. 2011, 100, 3655-3681 10.1002/jps.22568
14. Barrow, J. C. Inhibitors of Catechol-O-Methyltransferase CNS Neurol. Disord.: Drug Targets 2012, 11, 324-332 10.2174/187152712800672517
15. Vidgren, J.; Svensson, L. A.; Liljas, A. Crystal Structure of Catechol O-Methyltransferase Nature 1994, 368, 354-358 10.1038/368354a0
16. Pajouhesh, H.; Lenz, G. R. Medicinal Chemical Properties of Successful Central Nervous System Drugs NeuroRx 2005, 2, 541-553 10.1602/neurorx.2.4.541
17. Borchardt, R. T.; Wu, Y. S. Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 1. Modification of the Amino Acid Portion of S-Adenosylhomocysteine J. Med. Chem. 1974, 17, 862-868 10.1021/jm00254a016
18. Borchardt, R. T.; Wu, Y. S. Potential Inhibitors of S-Adenosylmethionine-dependent Methyltransferases. 3. Modifications of the Sugar Portion of S-Adenosylhomocysteine J. Med. Chem. 1975, 18, 300-304 10.1021/jm00237a018
19. Fuller, R. W.; Nagarajan, R. Inhibition of Methyltransferases by Some New Analogs of S-Adenosylhomocysteine Biochem. Pharmacol. 1978, 27, 1981-1983 10.1016/0006-2952(78)90018-7
20. Murray, C. W.; Verdonk, M. L.; Rees, D. C. Experiences in Fragment-Based Drug Discovery Trends Pharmacol. Sci. 2012, 33, 224-232 10.1016/j.tips.2012.02.006
21. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y. J.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma Nature 2010, 467, 596-599 10.1038/nature09454
22. For a comprehensive review on fragment-based approaches see the following: Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-Based Approaches in Drug Discovery and Chemical Biology Biochemistry 2012, 51, 4990-5003 10.1021/bi3005126
23. Huber, W. A New Strategy for Improved Secondary Screening and Lead Optimization Using High-Resolution SPR Characterization of Compound-Target Interactions J. Mol. Recognit. 2005, 18, 273-281 10.1002/jmr.744
24. Navratilova, I.; Hopkins, A. L. Fragment Screening by Surface Plasmon Resonance ACS Med. Chem. Lett. 2010, 1, 44-48 10.1021/ml900002k
25. Danielson, U. H. Fragment Library Screening and Lead Characterization Using SPR Biosensors Curr. Top. Med. Chem. 2009, 9, 1725-1735 10.2174/156802609790102392
26. Klages, J.; Coles, M.; Kessler, H. NMR-Based Screening: A Powerful Tool in Fragment-Based Drug Discovery Analyst 2007, 132, 692-705 10.1039/B709658P
27. Meiboom, S.; Gill, D. Modified Spin-Echo Method for Measuring Nuclear Relaxation Times Rev. Sci. Instrum. 1958, 29, 688-691 10.1063/1.1716296
28. Basse, N.; Kaar, J. L.; Settanni, G.; Joerger, A. C.; Rutherford, T. J.; Fersht, A. R. Toward the Rational Design of p53- Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant Chem. Biol. 2010, 17, 46-56 10.1016/j.chembiol.2009.12.011
29. Enderle, T.; Roth, D. Method for the Identification of Catechol O-Methyltransferase Modulators. WO/2012/013614 A1, 2012.
30. Mortenson, P. N.; Murray, C. W. Assessing the Lipophilicity of Fragments and Early Hits J. Comput.-Aided Mol. Des. 2011, 25, 663-667 10.1007/s10822-011-9435-z
31. Lanier, M.; Ambrus, G.; Cole, D. C.; Davenport, R.; Ellery, J.; Fosbeary, R.; Jennings, A. J.; Kadotani, A.; Kamada, Y.; Kamran, R.; Matsumoto, S.-I.; Mizukami, A.; Okubo, S.; Okada, K.; Saikatendu, K.; Walsh, L.; Wu, H.; Hixon, M. S. A Fragment-Based Approach to Identifying S-Adenosyl-L-Methionine -Competitive Inhibitors of Catechol O-Methyl Transferase (COMT) J. Med. Chem. 2014, 57, 5459-5463 10.1021/jm500475k
32. Zhang, J.; Klinman, J. P. Enzymatic Transfer; Role of and Active Site Residue in Generating Active Site Compaction that Correlates with Catalytic Efficiency J. Am. Chem. Soc. 2011, 133, 17134-17137 10.1021/ja207467d
33. Zhang, J.; Kulik, H. J.; Martinez, T. J.; Klinman, J. P. Mediation of Donor-Acceptor Distance in an Enzymatic Methyl Transfer Reaction Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 7954-7959 10.1073/pnas.1506792112
34. Tsuji, E.; Okazaki, K.; Isaji, M.; Takeda, K. Crystal Structures of the Apo and Holo Form of Rat Catechol-O-Methyltransferase J. Struct. Biol. 2009, 165, 133-139 10.1016/j.jsb.2008.11.012